Basic Information
Leucid Bio is a biotechnology company dedicated to providing a new generation of cell therapies for difficult-to-treat cancers. Established to translate 20 years of groundbreaking CAR-T research led by Dr. John Maher at King's College London, Leucid Bio has developed a patent portfolio based on Dr. Maher’s novel approach. This technology imparts characteristics to CAR-T that enable them to outperform previous generations of CAR-T therapies in preclinical studies, enhance the potency of T cells, and generate durable long-term responses, improving treatment outcomes and saving the lives of patients with refractory cancers.